Alligator Bioscience has expanded its research collaboration and license agreement with Orion Corp., a global pharmaceutical company based in Finland, to discover and develop new bispecific antibody cancer therapeutics.   The collaboration has been expanded to add the development of a second bispecific antibody using Alligator’s bispecific RUBY platform, where Alligator will provide validated monospecific binders for one target and Orion will do the same for the other target.   Under the ini...